About the HPTN

Mission Statement

The HPTN is dedicated to the discovery and development of new and innovative research strategies to reduce the acquisition and transmission of HIV.

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection.

The HPTN research agenda is focused primarily on the use of integrated strategies: use of antiretroviral drugs (antiretroviral therapy and pre-exposure prophylaxis); interventions for substance abuse, particularly injection drug use; behavioral risk reduction interventions and structural interventions. The HPTN is committed to the highest ethical standards for its clinical trials and recognizes the importance of community engagement in all phases of the research process.

The HPTN was established in 2000, building on the work of the HIV Network for Prevention Trials (HIVNET). HPTN’s Leadership and Operations Center (LOC), is based at FHI 360, Durham, North Carolina. Its Laboratory Center (LC) is at Johns Hopkins University, Baltimore, Maryland and its Statistical and Data Management Center (SDMC) is housed within the Statistical Center for HIV/AIDS Research and Prevention (SCHARP) at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The HPTN Modelling Centre, part of the SDMC, is a collaboration between the Department of Infectious Diseases Epidemiology at Imperial College London and SCHARP.

HPTN receives its funding from three NIH institutes: the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health and the National Institute on Drug Abuse.


The HPTN Leadership and Operations Center (LOC)

The HPTN Statistical and Data Management Center (SDMC)

Conversations with the HPTN

Nadir Cardozo, an HPTN 083 Community Working Group member, is part of the Community Participation and Social Research Team at Fundación Huésped in Buenos Aires. At the age of 20, Nadir had to migrate to Buenos Aires due to gender identity and stigma discrimination. Nadir is also an activist and trans-militant with the Association of Transvestites, Transsexuals, and Transgenders of Argentina (ATTITA).

Pongpun Saokhieo, a member of the HPTN 083 study team and community working group, is a study coordinator and community educator at the Chiang Mai HIV Prevention Clinical Research Site (CRS) in Thailand. She has supported HIV research trials through multiple networks for more than 18 years.

Rondalya DeShields, MSN, RN, a member of HPTN 064 and HPTN 102 study teams, is the director of the Infectious Disease Practice, Prevention, and Clinical Research Studies at Rutgers New Jersey Medical School Department of Medicine in New Jersey. She has more than 21 years of experience in HIV care, treatment, and prevention. Rondalya’s passion is to improve the lives of underserved populations with a focus on women and LGTBQ communities.

Dr. Manya Magnus, District of Columbia clinical trial unit leader, has been site principal investor for HPTN 083 among other HPTN studies, since 2008. She is a professor and interim chair of the Department of Epidemiology at the Milken Institute School of Public Health at George Washington University in Washington, D.C. Dr. Magnus is also the co-director of the school’s M.P.H.